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was for prescription medications, at $747,551,471 (mean
= $59.87; 95% CL = $51.95–$67.78). Ofﬁce-based
medical provider visits were $396,946,065 (mean =
$73.50; 95% CL = $60.20–$86.80). Emergency depart-
ment visits were approximately $110 million while out-
patient services, inpatient stays, and home health services
were each below $100 million. CONCLUSIONS: The
cost of treating a migraineur was estimated to be $293 in
1999, nearly 3 times higher than $100 reported in 1994.
However, total direct costs in 1999 were $1.5 billion,
only 50% higher than $1 billion reported in 1994. 
Prescription expenditures at greater than 50% of direct
costs were a major factor in the increase in incident cost.
The rate of increase in total costs was less than the rate
of increase in incident costs, suggesting either greater drug
efﬁcacy or reduced use of more costly medical care 
alternatives.
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OBJECTIVES: There is a wide array of pharmacological
agents available for the acute treatment of migraine
headache. The 5-HT1B/1D receptor agonists (triptans),
ergotamine derivatives, and isometheptene/dichlo-
ralphenazone combination products represent the most
frequently prescribed migraine-speciﬁc therapies. Our
objective is to describe the costs and explore the 
utilization patterns of migraine-speciﬁc therapies in the
Wisconsin Medicaid population. METHODS: Wisconsin
Medicaid drug utilization data for 2001 was used. These
data were obtained directly from the Centers for
Medicare & Medicaid Services website. National Drug
Codes were used to extract quarterly utilization data for
products belonging to three classes of acute migraine ther-
apies (triptans, ergotamine derivatives, and isomethep-
tene/dichloralphenazone combination products). Analysis
of utilization was performed for each quarter of 2001 by
aggregating the amount and number of claims reimbursed
across products. Further analysis was conducted to
examine the average cost per claim between pharma-
cological classes and individual triptan therapies.
RESULTS: In 2001, the Wisconsin Medicaid program
reimbursed acute-migraine drug treatment claims totaling
$2,372,463.66, representing 15,120 prescription claims.
Most of this expenditure (98.3%/$2,331,090.71) was 
a result of triptan claims, with 1.5 % ($34,715.25) and
0.2% ($6,657.70) representing ergotamine derivative and
isometheptene/dichloralphenazone combination product
claims, respectively. Within the triptan class, sumitriptan
(9,122/$1,599,212.19), rizatriptan (2,388/$306,947.59)
and zolmatriptan (1,877/$264,947.76) composed the
ﬁrst, second, and third most utilized products. Cost per
claim values within the oral triptans varied greatly 
with a high of $180.72 (sumitriptan) and a low of $81.51
(almotriptan). CONCLUSION: In the Wisconsin Medic-
aid population, utilization of migraine-speciﬁc therapies
was weighted heavily towards the triptans. With the large
variation in claims cost among oral triptans, consider-
able cost savings could be realized if a system was 
implemented to increase utilization of newer, second-
generation triptans (non-sumatriptan) as ﬁrst-line
therapy. However, such a clinical decision should be sup-
ported by comparative clinical trail data that supports
equivalent or superior efﬁcacy to sumatriptan.
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OBJECTIVE: Clinical recommendations advocate use of
carbamazepine, lamotrigine, and gabapentin rather than
phenobarbital and phenytoin for treating older patients
with epilepsy. We describe prescribing patterns for 
older veterans newly diagnosed with epilepsy, determine
if practice is consistent with clinical recommendations,
and describe those at greatest risk of receiving these
potentially inappropriate antiepileptic drugs (AEDs).
METHODS: Retrospective national inpatient, outpatient,
and pharmacy data from the Veterans Health Adminis-
tration (VA), were used to identify veterans >64 years
with an epilepsy diagnosis during ﬁscal year 1999 (FY99)
who also received AEDs from the VA in FY99. Patients
who were seen in the VA during FY97-98 with no 
previous diagnosis of epilepsy were selected. We identi-
ﬁed patients’ AED regimen for FY99, demographic char-
acteristics, neurology consultations, and disease severity.
We used logistic regression to identify patients most likely
to receive phenobarbital and phenytoin. RESULTS:
Eighty-ﬁve percent received monotherapy. Ten percent 
of patients received regimens containing phenobarbital,
68% received regimens including phenytoin, and 25%
received only recommended AEDs. Logistic regression
analyses indicated that patients with more severe disease
were less likely to receive phenobarbital monotherapy
than other monotherapy (OR: 0.47, 95% CI 0.22–0.98)
and phenobarbital combinations than other combina-
tions (OR: 0.29, 95% CI 0.13–0.70). Patients receiving
neurology consultation were less likely to receive pheny-
toin monotherapy than monotherapies consistent with
clinical recommendations (New OR: 0.49, 95% CI
0.39–0.61). CONCLUSIONS: A surprising number of
newly diagnosed veterans received phenobarbital despite
its well known adverse effects. Moreover, our ﬁnding 
that nearly 70% receive phenytoin is not consistent with
